IGF1 and hepatocellular carcinoma: Although the study of IGF-1 as a biomarker for the treatment of HCC with SBRT is novel, the main shortcomings of this study were the relatively small sample size and the heterogeneity of the disease groups, which might limit the generalizability of the findings to a broader population.